OverviewSuggest Edit

Our first test for uveal melanoma, a rare and deadly eye cancer, is used to identify those at high risk for metastasis. With demonstrated improved accuracy over existing staging and prognostic tools, the test has become the standard of care for uveal melanoma and has successfully secured reimbursement. We are using its innovation as a model for our growing lineup of practice-changing tests, including our newer cutaneous (skin) melanoma prognostic assay. We have active development programs for assays in several other underserved cancers.
Castle Biosciences’ tests are performed in a CLIA-certified, CAP-accredited clinical laboratory.

TypePublic
Founded2008
HQFriendswood, US
Websitecastlebiosciences.com

Recent NewsAll News

Latest Updates

Employees (est.) (Jul 2019)91(+2%)
Revenue (FY, 2019)$51.9 M(+128%)
Share Price (Sept 2020)$50.3 (-2%)
Cybersecurity ratingBMore

Key People/Management at Castle Biosciences

Derek Maetzold

Derek Maetzold

Founder, President, and CEO
Bernhard E. Spiess

Bernhard E. Spiess

COO
Federico Monzon

Federico Monzon

Chief Medical Officer
Frank Stokes

Frank Stokes

CFO
Toby Juvenal

Toby Juvenal

Senior Vice President, Sales
Kristen Oelschlager

Kristen Oelschlager

Senior Vice President, Operations
Show more

Castle Biosciences Office Locations

Castle Biosciences has offices in Friendswood and Phoenix
Friendswood, US (HQ)
820 S Friendswood Dr #201
Phoenix, US
3737 N 7th St #160
Show all (2)

Castle Biosciences Financials and Metrics

Castle Biosciences Revenue

Embed Graph
View revenue for all periods
Castle Biosciences's revenue was reported to be $51.87 m in FY, 2019
USD

Revenue (Q2, 2020)

12.7m

Gross profit (Q2, 2020)

10.6m

Gross profit margin (Q2, 2020), %

83.1%

Net income (Q2, 2020)

(1.4m)

EBIT (Q2, 2020)

(645.0k)

Market capitalization (23-Sept-2020)

989.8m

Closing stock price (23-Sept-2020)

50.3

Cash (30-Jun-2020)

179.8m

EV

834.8m
Castle Biosciences's current market capitalization is $989.8 m.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

13.8m22.8m51.9m

Revenue growth, %

66%

Cost of goods sold

4.9m5.3m7.3m

Gross profit

8.8m17.5m44.6m
Quarterly
USDQ1, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

3.7m8.7m10.7m14.8m17.4m12.7m

Cost of goods sold

1.3m1.6m2.0m1.7m2.4m2.1m

Gross profit

2.4m7.1m8.7m13.1m15.0m10.6m

Gross profit Margin, %

66%82%81%88%86%83%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

1.2m4.5m98.8m

Accounts Receivable

4.7m12.1m14.6m

Prepaid Expenses

515.5k675.6k2.0m

Inventories

304.6k882.2k1.2m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

16.2m17.5m94.5m98.7m179.8m

Accounts Receivable

9.2m9.7m12.4m14.6m12.5m

Prepaid Expenses

741.4k774.9k2.2m2.1m1.7m

Inventories

809.3k550.9k821.7k1.2m1.7m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(12.4m)(6.4m)5.3m

Depreciation and Amortization

270.3k287.1k358.0k

Inventories

(115.6k)(577.7k)(355.0k)

Accounts Payable

370.9k197.2k557.0k
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q1, 2020Q2, 2020

Net Income

(3.6m)(2.6m)3.2m(1.4m)570.0k(806.0k)

Depreciation and Amortization

70.4k167.5k258.5k77.4k91.0k193.0k

Inventories

97.0k331.3k60.6k97.0k19.0k(430.0k)

Accounts Payable

(217.2k)(524.0k)(46.9k)(328.8k)56.0k444.0k
USDFY, 2017

Revenue/Employee

215.5k

Debt/Equity

-1.3 x

Debt/Assets

1.9 x

Financial Leverage

-0.7 x
Show all financial metrics

Castle Biosciences Operating Metrics

Q1, 2019

Clinical Samples Processed to Date

40 k
Show all operating metrics

Castle Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Castle Biosciences Online and Social Media Presence

Embed Graph

Castle Biosciences News and Updates

VC-backed Castle Biosciences goes public

Friendswood, Texas-based Castle Biosciences Inc, a dermatological cancer company, has raised $64 million for its IPO after pricing its 4 million shares at $16 per share. The stock began trading July 25, 2019 on the NASDAQ under the ticker symbol "CSTL." SVB Leerink and Baird are the lead underwriter…

Castle Biosciences Blogs

Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk

Data presented at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting FRIENDSWOOD, Texas–(BUSINESS WIRE)–Oct. 31, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, to…

Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Oct. 29, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of a development update and validation data for its cutaneou…

Castle Biosciences to Release Third Quarter 2019 Financial Results and Host Conference Call on Monday, November 11, 2019

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Oct. 28, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that it will release its financial results for the third quarter ended Septem…

Castle Biosciences Presents Second Study Confirming Ability of DecisionDx-Melanoma to Inform Sentinel Lymph Node Biopsy Decisions at the 8th International Congress on Cancer Metastasis

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Oct. 28, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of data supporting clinical use of the DecisionDx®-Melanoma …

Castle Biosciences Presents Data at the ASDP 56th Annual Meeting Supporting DecisionDx-Melanoma Test’s Ability to Identify T1 Melanoma Patients at Low Risk for a Positive Sentinel Lymph Node

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Oct. 18, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of data supporting the ability of the DecisionDx®-Melanoma g…

Castle Biosciences Announces Presentation of Prospective, Multicenter Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma

Data presented at American Academy of Ophthalmology 2019 Annual Meeting FRIENDSWOOD, Texas–(BUSINESS WIRE)–Oct. 16, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions in skin cancers and uv…
Show more

Castle Biosciences Frequently Asked Questions

  • When was Castle Biosciences founded?

    Castle Biosciences was founded in 2008.

  • Who are Castle Biosciences key executives?

    Castle Biosciences's key executives are Derek Maetzold, Bernhard E. Spiess and Federico Monzon.

  • How many employees does Castle Biosciences have?

    Castle Biosciences has 91 employees.

  • What is Castle Biosciences revenue?

    Latest Castle Biosciences annual revenue is $51.9 m.

  • What is Castle Biosciences revenue per employee?

    Latest Castle Biosciences revenue per employee is $569.9 k.

  • Who are Castle Biosciences competitors?

    Competitors of Castle Biosciences include Biodesy, Laboratory Corporation of America Holdings and Astute Medical.

  • Where is Castle Biosciences headquarters?

    Castle Biosciences headquarters is located at 820 S Friendswood Dr #201, Friendswood.

  • Where are Castle Biosciences offices?

    Castle Biosciences has offices in Friendswood and Phoenix.

  • How many offices does Castle Biosciences have?

    Castle Biosciences has 2 offices.